Crinetics Pharmaceuticals Stock Analysis
| CRNX Stock | USD 31.11 1.91 5.78% |
Crinetics Pharmaceuticals is undervalued with Real Value of 40.25 and Hype Value of 30.98. The main objective of Crinetics Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Crinetics Pharmaceuticals is worth, separate from its market price. There are two main types of Crinetics Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Crinetics Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Crinetics Pharmaceuticals is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Crinetics Stock trading window is adjusted to America/New York timezone.
Crinetics | Build AI portfolio with Crinetics Stock |
Crinetics Stock Analysis Notes
About 98.0% of the company shares are held by institutions such as insurance companies. The book value of Crinetics Pharmaceuticals was currently reported as 13.41. The company recorded a loss per share of 3.8. Crinetics Pharmaceuticals had not issued any dividends in recent years. Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Crinetics Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 143 people. For more info on Crinetics Pharmaceuticals please contact Scott Struthers at 858 450 6464 or go to https://www.crinetics.com.Crinetics Pharmaceuticals Investment Alerts
| Crinetics Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 1.04 M. Net Loss for the year was (298.41 M) with loss before overhead, payroll, taxes, and interest of (262.3 M). | |
| Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (225.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6. | |
| Crinetics Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are held by institutions such as insurance companies |
Crinetics Pharmaceuticals Upcoming and Recent Events
Earnings reports are used by Crinetics Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Crinetics Market Capitalization
The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.09 B.Technical Drivers
As of the 19th of July, Crinetics Pharmaceuticals shows the Mean Deviation of 2.28, risk adjusted performance of 0.0366, and Downside Deviation of 3.23. Crinetics Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Crinetics Pharmaceuticals Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Simple Moving Average indicator is calculated by adding the closing price of Crinetics Pharmaceuticals for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out Crinetics Pharmaceuticals short-term fluctuations and highlight longer-term trends or cycles.
Crinetics Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Crinetics Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Crinetics Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Crinetics Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Crinetics Pharmaceuticals Outstanding Bonds
Crinetics Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Crinetics Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Crinetics bonds can be classified according to their maturity, which is the date when Crinetics Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Crinetics Pharmaceuticals Predictive Daily Indicators
Crinetics Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Crinetics Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Crinetics Pharmaceuticals Forecast Models
Crinetics Pharmaceuticals' time-series forecasting models are one of many Crinetics Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Crinetics Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Crinetics Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Crinetics Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Crinetics shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Crinetics Pharmaceuticals. By using and applying Crinetics Stock analysis, traders can create a robust methodology for identifying Crinetics entry and exit points for their positions.
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Crinetics Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 143 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Crinetics Pharmaceuticals to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.